To determine the effect of intravenous nimodipine on delayed ischemic deterioration and computerized tomography (CT)-visualized infarcts after SAH and surgery.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Double-blind, randomized, placebo-controlled trial of 213 patients.
Patients were randomized to receive nimodipine (0.5 ug/kg/min) intravenously for 7 to 10 days following SAH and orally (60 mg every four hours) thereafter for a total of 21 days or placebo. Treatment was started immediately after the diagnosis of a ruptured aneurysm had been made and at least 2 hours prior to surgery. Patients were followed for 1 to 3 years.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Glasgow Outcome Scale 1 to 3 years post SAH.|